Biocon partners with Tabuk Pharma to commercialize GLP -1 products in Middle East region

Bengaluru: Biocon Limited, a global biopharmaceutical company, has announced the signing of a licensing and supply agreement with Tabuk Pharmaceutical Manufacturing
Company, (a fully-owned subsidiary of Astra Industrial Group), a pharmaceutical company in the Middle
East and North Africa (MENA) region, to commercialize its GLP-1 products for treating diabetes and chronic
weight management, in select countries of the Middle East.

Under the terms of this agreement, Biocon will develop and manufacture the products and Tabuk
Pharmaceuticals will hold the marketing authorization rights, and be responsible to register, import, and
promote them in the region. The agreement also provides for a provision to expand to other GLP products, as
well as the option of a tech transfer that will enable localized manufacturing at a later stage.

Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon Ltd, said, “I am pleased to expand
our partnership with Tabuk Pharmaceuticals, which paves the way for our vertically integrated, complex GLP1 formulations entry into Saudi Arabia and other countries in the region. The partnership is further validation
of our concerted focus on GLPs and Peptides as future growth drivers. This is another important milestone for
Biocon, reflecting our commitment to providing patients around the globe with affordable medications, by
establishing a strong portfolio of products, either directly or through strategic partnerships.”

Commenting on the development, Ismail Shehadah, Chief Executive Officer of Tabuk Pharmaceuticals,
added, “We are excited to announce our partnership with Biocon that will enable us to deliver unique health
solutions aimed at enhancing the well-being of people in Saudi Arabia and other countries we operate in. We
are confident that this partnership supports our efforts to manufacture and localize a range of GLP-1 products
in the region and strengthen our market leading position in the area of diabetes medications, in line with our
strategy. This also stands as a commitment from our side to support the 2030 vision of Saudi Arabia through
localizing specialty pharmaceutical products in the Kingdom.”

Read also: Biocon Biologics announces New Dermatology data to be presented at EADV Congress 2024